MS News that Caught My Eye Last Week: Mayzent in EU for SPMS; Depression, Fatigue, and Quality of Life; Acthar Gel; Soothie Cushion
CHMP Favors Mayzent as Oral Treatment Specifically for Active SPMS Patients in EU Mayzent (siponimod) is one of the newest disease-modifying treatments (DMT). I’m pleased that the Committee for Medicinal Products of Human Use (CHMP), which reviews treatments in the European Union, has recommended that the DMT be approved…